ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2005
Drug transport to brain with targeted liposomes.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 208 citations in OpenAlex.
- Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.International journal of nanomedicine · 2015Pooled it
- E-selectin and transferrin receptor functionalized synthetic miRNA nanoshuttles with therapeutic potential in stroke.Drug delivery and translational research · 2026Article
- Liposomal nanoprobes actuated by engineered water channels for sensitive detection of molecular targets by MRI.Nature biomedical engineering · 2026Article
- Tracking the morphological evolution of neuronal dendrites by first-passage analysis.Biophysical journal · 2026Article
- Using Immunoliposomes as Carriers to Enhance the Therapeutic Effectiveness of Macamide N-3-Methoxybenzyl-Linoleamide.Neurology international · 2025Article
- Liposomal Drug Delivery for Neurological Disorders: Advances and Challenges.Central nervous system agents in medicinal chemistry · 2025Review
- Role of Liposomes in the Treatment of Neurodegenerative Disorders: A Comprehensive Review.Central nervous system agents in medicinal chemistry · 2025Review
- Isoquercitrin Loaded PEGylated Long Circulating Liposomes Improve Bone Mass and Reduce Oxidative Stress After Osteoporosis.AAPS PharmSciTech · 2024Article
- Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges.European journal of medical research · 2024Review
- Liposome-Mediated Anti-Viral Drug Delivery Across Blood-Brain Barrier: Can Lipid Droplet Target Be Game Changers?Cellular and molecular neurobiology · 2023Review
- Single and Multitarget Systems for Drug Delivery and Detection: Up-to-Date Strategies for Brain Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Role of Biological Rhythms in New Drug Formulations to Cross the Brain Barriers.International journal of molecular sciences · 2023Review
- TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems.Pharmaceutical research · 2023Review
- Glaucoma Treatment and Hydrogel: Current Insights and State of the Art.Gels (Basel, Switzerland) · 2022Review
- Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity againstPharmaceutics · 2022Article
- Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance.Molecules (Basel, Switzerland) · 2021Review
- Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions.Pharmaceutics · 2020Review
- Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma.Nanoscale · 2020Article
- Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment.International journal of nanomedicine · 2020Review
- Evaluation of Targeted Delivery to the Brain Using Magnetic Immunoliposomes and Magnetic Force.Materials (Basel, Switzerland) · 2019Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-conjugated liposomes or immunoliposomes are particulate drug carriers that can be used to direct encapsulated drug molecules to diseased tissues or organs. The present review discusses examples of successful applications of this technology to achieve drug transport across the blood-brain barrier. In addition, information will be provided on practical aspects such as phospholipid compositions of liposomes, antibody coupling technologies, large-scale production of liposomes, and obstacles related to drug loading of the carrier. Prospects of future uses of immunoliposome-based drug delivery systems such as gene therapy of the brain and clinical trials are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.